AIMS: To determine whether the G(-174)C interleukin 6 (IL-6) polymorphism influences the development of peripheral arterial disease (PAD) in individuals with type 2 diabetes. This was investigated by comparing the distribution of G(-174)C genotypes between patients with type 2 diabetes and PAD (PAD+) and those with type 2 diabetes but without PAD (PAD-). Plasma concentrations of IL-6, fibrinogen, C reactive protein (CRP), and vascular endothelial growth factor (VEGF) were also compared in PAD+ and PAD- patients. METHODS: Blood samples were collected from 146 PAD+ and 144 PAD- patients. SfaNI was used to determine the G(-174)C genotype. Plasma concentrations of IL-6, fibrinogen, CRP, and VEGF were measured by an enzyme linked immunosorbent assay. RESULTS: The GG genotype was more common in PAD+ patients than in PAD- patients. PAD+ patients also had increased mean plasma concentrations of IL-6, fibrinogen, CRP, and VEGF compared with PAD- patients. Mean plasma concentrations of IL-6, fibrinogen, and CRP in both PAD+ and PAD- patients were higher in those with the GG genotype than in those with the GC or CC genotypes. In contrast, mean plasma concentrations of VEGF in PAD+ and PAD- patients were not significantly different between those with different G(-174)C genotypes. CONCLUSIONS: These results support a model in which the GG genotype promotes PAD development among individuals with type 2 diabetes by inducing increased release of IL-6. Higher concentrations of IL-6 among those with the GG genotype is associated with increased plasma concentrations of fibrinogen and CRP.
AIMS: To determine whether the G(-174)C interleukin 6 (IL-6) polymorphism influences the development of peripheral arterial disease (PAD) in individuals with type 2 diabetes. This was investigated by comparing the distribution of G(-174)C genotypes between patients with type 2 diabetes and PAD (PAD+) and those with type 2 diabetes but without PAD (PAD-). Plasma concentrations of IL-6, fibrinogen, C reactive protein (CRP), and vascular endothelial growth factor (VEGF) were also compared in PAD+ and PAD- patients. METHODS: Blood samples were collected from 146 PAD+ and 144 PAD- patients. SfaNI was used to determine the G(-174)C genotype. Plasma concentrations of IL-6, fibrinogen, CRP, and VEGF were measured by an enzyme linked immunosorbent assay. RESULTS: The GG genotype was more common in PAD+ patients than in PAD- patients. PAD+ patients also had increased mean plasma concentrations of IL-6, fibrinogen, CRP, and VEGF compared with PAD- patients. Mean plasma concentrations of IL-6, fibrinogen, and CRP in both PAD+ and PAD- patients were higher in those with the GG genotype than in those with the GC or CC genotypes. In contrast, mean plasma concentrations of VEGF in PAD+ and PAD- patients were not significantly different between those with different G(-174)C genotypes. CONCLUSIONS: These results support a model in which the GG genotype promotes PAD development among individuals with type 2 diabetes by inducing increased release of IL-6. Higher concentrations of IL-6 among those with the GG genotype is associated with increased plasma concentrations of fibrinogen and CRP.
Authors: Nancy S Jenny; Russell P Tracy; Malcolm S Ogg; Le Ahn Luong; Lewis H Kuller; Alice M Arnold; A Richey Sharrett; Steve E Humphries Journal: Arterioscler Thromb Vasc Biol Date: 2002-12-01 Impact factor: 8.311
Authors: K G Jones; D J Brull; L C Brown; M Sian; R M Greenhalgh; S E Humphries; J T Powell Journal: Circulation Date: 2001-05-08 Impact factor: 29.690
Authors: F Burzotta; L Iacoviello; A Di Castelnuovo; F Glieca; N Luciani; R Zamparelli; R Schiavello; M B Donati; A Maseri; G Possati; F Andreotti Journal: Am J Cardiol Date: 2001-11-15 Impact factor: 2.778
Authors: Markus Nauck; Bernhard R Winkelmann; Michael M Hoffmann; Bernhard O Böhm; Heinrich Wieland; Winfried März Journal: J Mol Med (Berl) Date: 2002-06-21 Impact factor: 4.599
Authors: A Flex; E Gaetani; R Pola; A Santoliquido; F Aloi; P Papaleo; A Dal Lago; E Pola; M Serricchio; P Tondi; P Pola Journal: Eur J Vasc Endovasc Surg Date: 2002-09 Impact factor: 7.069
Authors: Joanne M Murabito; Michelle J Keyes; Chao-Yu Guo; John F Keaney; Ramachandran S Vasan; Ralph B D'Agostino; Emelia J Benjamin Journal: Atherosclerosis Date: 2008-07-09 Impact factor: 5.162
Authors: Radosław Wieczór; Grażyna Gadomska; Barbara Ruszkowska-Ciastek; Katarzyna Stankowska; Jacek Budzyński; Jacek Fabisiak; Karol Suppan; Grzegorz Pulkowski; Danuta Rość Journal: J Zhejiang Univ Sci B Date: 2015-11 Impact factor: 3.066